Literature DB >> 26852906

Association of copy number polymorphisms at the promoter and translated region of COMT with Japanese patients with schizophrenia.

Ryoko Higashiyama1, Tohru Ohnuma1, Yuto Takebayashi1, Ryo Hanzawa1, Nobuto Shibata1, Hidenaga Yamamori2, Yuka Yasuda2, Itaru Kushima3, Branko Aleksic3, Kenji Kondo4, Masashi Ikeda4, Ryota Hashimoto2,5, Nakao Iwata4, Norio Ozaki3, Heii Arai1.   

Abstract

Chromosome 22q11.2 deletion syndrome and genetic variations including single-nucleotide polymorphism (SNP) and copy number variation (CNV) in catechol-O-methyltransferase (COMT) situated at 22q11.2 remains controversial. Here, the genetic relationship between COMT and Japanese patients with schizophrenia was investigated by examining whether the SNPs correlated with schizophrenia based on a common disease-common variant hypothesis. Additionally, 22q11.2DS were screened based on a common disease-rare variant hypothesis; low-frequency CNVs situated at two COMT promoters and exons were investigated based on the low-frequency variants with an intermediate effect; and positive findings from the first stage were reconfirmed using a second-stage replication study including a larger sample size. Eight SNPs and 10 CNVs were investigated using Taqman SNP and CNV quantitative real-time polymerase chain reaction method. For the first-stage analysis, 513 unrelated Japanese patients with schizophrenia and 705 healthy controls were examined. For the second-stage replication study, positive findings from the first stage were further investigated using a larger sample size, namely 1,854 patients with schizophrenia and 2,137 controls. The first-stage analysis showed significant associations among schizophrenia, intronic SNP rs165774, CNV6 situated at promoter 1, CNV8 at exon 6, and CNV9 at exon 7. The second-stage study showed that intronic SNP rs165774 (χ(2)  = 8.327, P = 0.0039), CNV6 (χ(2)  = 19.66, P = 0.00005), and CNV8 (χ(2)  = 16.57, P = 0.00025) were significantly associated with schizophrenia. Large and rare CNVs as well as low-frequency CNVs and relatively small CNVs, namely <30 kb in COMT, may be genetic risk factors for schizophrenia.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  22q11.2; catechol-O-methyltransferase; copy number variation; schizophrenia; single-nucleotide polymorphism

Mesh:

Substances:

Year:  2016        PMID: 26852906     DOI: 10.1002/ajmg.b.32426

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  4 in total

1.  The coexistence of copy number variations (CNVs) and single nucleotide polymorphisms (SNPs) at a locus can result in distorted calculations of the significance in associating SNPs to disease.

Authors:  Jiaqi Liu; Yangzhong Zhou; Sen Liu; Xiaofei Song; Xin-Zhuang Yang; Yanhui Fan; Weisheng Chen; Zeynep Coban Akdemir; Zihui Yan; Yuzhi Zuo; Renqian Du; Zhenlei Liu; Bo Yuan; Sen Zhao; Gang Liu; Yixin Chen; Yanxue Zhao; Mao Lin; Qiankun Zhu; Yuchen Niu; Pengfei Liu; Shiro Ikegawa; You-Qiang Song; Jennifer E Posey; Guixing Qiu; Feng Zhang; Zhihong Wu; James R Lupski; Nan Wu
Journal:  Hum Genet       Date:  2018-07-17       Impact factor: 4.132

2.  Potential link between genetic polymorphisms of catechol-O-methyltransferase and dopamine receptors and treatment efficacy of risperidone on schizophrenia.

Authors:  Jiyang Han; Yan Li; Xumei Wang
Journal:  Neuropsychiatr Dis Treat       Date:  2017-12-05       Impact factor: 2.570

3.  Association between COMT gene rs165599 SNP and schizophrenia: A meta-analysis of case-control studies.

Authors:  Harika Gozde Gozukara Bag
Journal:  Mol Genet Genomic Med       Date:  2018-08-30       Impact factor: 2.183

Review 4.  Neuroimaging studies within Cognitive Genetics Collaborative Research Organization aiming to replicate and extend works of ENIGMA.

Authors:  Daisuke Koshiyama; Kenichiro Miura; Kiyotaka Nemoto; Naohiro Okada; Junya Matsumoto; Masaki Fukunaga; Ryota Hashimoto
Journal:  Hum Brain Mapp       Date:  2020-06-05       Impact factor: 5.038

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.